Nat. Med. :乳腺癌细胞能够关闭干扰素生产和躲避免疫反应

2012-07-25 ZinFingerNase 生物谷

干扰素是一种免疫反应蛋白,身体利用这种蛋白对抗病毒和细菌感染。在一项新研究中,研究人员发现某些乳腺癌细胞能够关闭负责导致干扰素产生的基因。因为这一发现,于2012年7月22日在线发表在Nature Medicine期刊上的一篇论文中,他们写道,癌细胞能够在不遭受免疫系统攻击的情况下转移到身体其他部分,特别是骨组织中。 在这项新研究中,为了更好地了解当癌症从乳腺转移到身体其他部分时会发生什么,研究

干扰素是一种免疫反应蛋白,身体利用这种蛋白对抗病毒和细菌感染。在一项新研究中,研究人员发现某些乳腺癌细胞能够关闭负责导致干扰素产生的基因。因为这一发现,于2012年7月22日在线发表在Nature Medicine期刊上的一篇论文中,他们写道,癌细胞能够在不遭受免疫系统攻击的情况下转移到身体其他部分,特别是骨组织中。

在这项新研究中,为了更好地了解当癌症从乳腺转移到身体其他部分时会发生什么,研究人员从乳腺癌病人和小鼠解剖标本中收集组织样品。在研究这些样品过程中,他们发现癌细胞能够关闭癌症转移到身体其他部分的人和小鼠中的基因IRF7。当检测到感染存在时,IRF7负责促进干扰素产生。抑制干扰素产生而阻止免疫反应,从而使得癌细胞轻易地转移到骨髓中。因此,癌细胞能够伪装它们的存在并躲避它们的攻击者。

为了抵消这种效果,研究人员尝试了两种方法。在第一种方法中,他们试着以癌细胞不能关闭干扰素产生的方式将干扰素基因导入细胞内。第二种方法涉及将干扰素注射到实验小鼠体内。他们报道这两种方法都能有效地阻止癌细胞转移。不过,他们也说,在病人能够接受这些治疗之前,还需开展更多测试。

本文编译自Study finds breast cancer cells able to turn off interferon production to avoid immune response

doi: 10.1038/nm.2830
PMC:
PMID:

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

Bradley N Bidwell, Clare Y Slaney, Nimali P Withana et al.

Breast cancer metastasis is a key determinant of long-term patient survival. By comparing the transcriptomes of primary and metastatic tumor cells in a mouse model of spontaneous bone metastasis, we found that a substantial number of genes suppressed in bone metastases are targets of the interferon regulatory factor Irf7. Restoration of Irf7 in tumor cells or administration of interferon led to reduced bone metastases and prolonged survival time. In mice deficient in the interferon (IFN) receptor or in natural killer (NK) and CD8+ T cell responses, metastasis was accelerated, indicating that Irf7-driven suppression of metastasis was reliant on IFN signaling to host immune cells. We confirmed the clinical relevance of these findings in over 800 patients in which high expression of Irf7-regulated genes in primary tumors was associated with prolonged bone metastasis–free survival. This gene signature may identify patients that could benefit from IFN-based therapies. Thus, we have identified an innate immune pathway intrinsic to breast cancer cells, the suppression of which restricts immunosurveillance to enable metastasis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879325, encodeId=c58518e932595, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 24 20:13:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251904, encodeId=40d2125190484, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280114, encodeId=0c731280114f5, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517677, encodeId=2fe8151e677cc, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605794, encodeId=a86c1605e94b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2013-03-24 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879325, encodeId=c58518e932595, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 24 20:13:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251904, encodeId=40d2125190484, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280114, encodeId=0c731280114f5, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517677, encodeId=2fe8151e677cc, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605794, encodeId=a86c1605e94b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-07-27 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879325, encodeId=c58518e932595, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 24 20:13:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251904, encodeId=40d2125190484, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280114, encodeId=0c731280114f5, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517677, encodeId=2fe8151e677cc, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605794, encodeId=a86c1605e94b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879325, encodeId=c58518e932595, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 24 20:13:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251904, encodeId=40d2125190484, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280114, encodeId=0c731280114f5, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517677, encodeId=2fe8151e677cc, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605794, encodeId=a86c1605e94b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1879325, encodeId=c58518e932595, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Mar 24 20:13:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251904, encodeId=40d2125190484, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280114, encodeId=0c731280114f5, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517677, encodeId=2fe8151e677cc, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605794, encodeId=a86c1605e94b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:13:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]

相关资讯

诺华药物Afinitor治疗乳腺癌疗效较好

2012年7月23日讯 -- 诺华(Novartis)药物Afinitor赢得了一个令人垂涎的新适应症--晚期乳腺癌。一项涉及724名女性的III期临床试验表明,Afinitor+Aromasin使癌症的恶化平均推迟了7.8个月,比Aromasin+安慰剂获得了4.6个月的改善。 这一新适应症有望使Afinitor成为诺华的重磅药物,分析师预计,这一新适应症将使Afinitor的销售峰值增加15

Clin Cancer Res:RB通路断裂提高乳腺癌新辅助化疗效果

     《临床癌症研究》(Clin Cancer Res)杂志近期发表的一项研究表明,RB通路断裂与乳腺癌对新辅助化疗反应情况改善有关;RB状态与乳腺癌对新辅助化疗反应情况有关,可用于指导治疗。   该研究旨在确定RB肿瘤抑制基因通路失调是否与乳腺癌(BC)对新辅助化疗反应情况改善有关。   在涉及3个不同新辅助化疗方案的基因表达数据集合中,一个RB缺失标志物被用于分析

BJC:CACNA2D3基因甲基化可预测乳腺癌扩散风险

在一项新研究中,给一个癌基因加上一种分子“便利贴(post-it note)”能够预测患者乳腺癌扩散的风险。 来自英国伦敦帝国学院(Imperial College London)的英国癌症研究中心研究人员证实CACNA2D3基因上高水平的被称作甲基化的分子修饰与乳腺癌患者体内这种疾病的扩散相关联。2012年7月10日,相关研究成果发表在British Journal of Cancer期刊上。

Mol Cell:癌症细胞对赫赛汀产生耐药的原因

乳腺癌疗法,如以HER2为靶点赫赛汀疗法给增加了许多女性的开支;然而近一半的乳腺癌从一开始治疗就对赫赛汀产生了耐药。如今来自密歇根大学癌症研究中心的科学家发现了癌症细胞为何如此耐药的原因,研究者表示,癌细胞完全是通过另外一种路径来作用的,其中一种涉及炎症,这就为癌细胞不依赖HER2为靶点提供了基础。 这种途径涉及一种蛋白质名为白介素-6(IL-6),研究人员在小鼠中进行实验,解释了一种药物可以阻

Cancer Res:富含半胱氨酸蛋白CCN6调节乳腺癌转移

在乳腺癌中,CCN6是一种细胞外基质蛋白,在疾病早期其表达是下降的,因此认为CCN6能发挥肿瘤抑制功能。然而,无论其作用还是在乳腺癌转移中作用机制都是未知的。 骨形态发生蛋白(BMPs)构成TGF-β超家族的配体,是诱导上皮间质转化(EMT)、细胞的侵袭和转移的多功能细胞因子。在这项最新研究中,科研人员确定CCN6-BMP4-TAK1蛋白激酶信号通路控制p38 MAP激酶,调节腺泡形态和乳腺癌细

治疗乳腺癌脑转移:如何突破屏障?

       美国Dana-Farber癌症研究所的Nancy U. Lin博士在哈佛医学院主办的一场乳腺癌会议上指出,尽管乳腺癌脑转移非常可怕,但近期在部分患者中取得的突破性进展提示其“恐怖统治”有望被打破。        随着治疗水平提高,身患进展期乳腺癌仍能生存的女性队伍日益壮大,而乳腺癌脑转移的发生率也随